Safety and 1‐Year Outcomes After Transplanting Hearts From SARS‐CoV‐2 Positive Donors: Insights From an International Analysis
Immunity, Inflammation and Disease · 2025
DOI: 10.1002/iid3.70252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2025. Verfasst von Sabina P W Guenther und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr-University Bochum, Bad Oeynhausen, Germany. Hauptthemen laut MEDLINE: Heart Transplantation, COVID-19, SARS-CoV-2, Tissue Donors. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Uncertainties persist regarding the utilization of hearts from SARS‐CoV‐2‐positive donors for heart transplant (HT). This international study analyzed such HTs within the United States (US) and Germany, focusing on 1‐year outcomes and granular safety data.
Methods
Data was obtained from the United Network for Organ Sharing (UNOS) registry (03/2021–08/2022) and collaborating with the German Organ Procurement Organisation (DSO; 03/2022–02/2023). HTs from currently and recently (up to 21 days in UNOS and 90 days in DSO) SARS‐CoV‐2‐positive donors were included.
Results
In the US, 274 HTs from SARS‐CoV‐2 donors were analyzed (50.7% SARS‐CoV‐2‐positive until organ recovery). Compared to 3952 HTs from SARS‐CoV‐2‐negative donors, acute rejection was less frequent (10.6% vs. 17.1%, p = 0.006). One‐year graft and recipient survival ( p = 0.327) and rehospitalization rates ( p = 0.592) did not differ. In Germany, 30 HTs utilized SARS‐CoV‐2‐positive hearts. Follow‐up was obtained for 23 (76.7%). 43.5% of the donors were positive until recovery. Two recipients (8.7%) tested positive for SARS‐CoV‐2 21 and 65 days post‐transplant, both unlikely donor‐derived. 8.7% had severe PGD, 8.7% acute cellular rejection ≥ 2R. One‐year survival was 91.3%. None experienced myocarditis or thromboembolism.
Conclusion
Using selected SARS‐CoV‐2‐positive hearts for transplant appears safe with no differences in 1‐year survival, no evidence of viral transmission or SARS‐CoV‐2‐related adverse cardiovascular events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr-University Bochum, Bad Oeynhausen, Germany.
- German Organ Procurement Organisation (DSO), Germany.
- Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.
- Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California, USA.
ORCID-Profile: Sabina P W Guenther, Henrik Fox
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Guenther, S. P. W., Wadewitz, J., Wayda, B. J., Fox, H., Cheaban, R., Shudo, Y., Hiesinger, W., Costard-Jäckle, A., Morshuis, M., Woo, Y. J., Teuteberg, J. J., Schramm, R., Rahmel, A., Gummert, J. F., & Khush, K. K. (2025). Safety and 1‐Year Outcomes After Transplanting Hearts From SARS‐CoV‐2 Positive Donors: Insights From an International Analysis. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70252
Vancouver
Guenther SPW, Wadewitz J, Wayda BJ, Fox H, Cheaban R, Shudo Y, et al. Safety and 1‐Year Outcomes After Transplanting Hearts From SARS‐CoV‐2 Positive Donors: Insights From an International Analysis. Immunity, Inflammation and Disease. 2025. doi:10.1002/iid3.70252
BibTeX
@article{Guenther2025,
author = {Guenther, Sabina P W and Wadewitz, Josephine and Wayda, Brian J and Fox, Henrik and Cheaban, Rayan and Shudo, Yasuhiro and Hiesinger, William and Costard-Jäckle, Angelika and Morshuis, Michiel and Woo, Y Joseph and Teuteberg, Jeffrey J and Schramm, René and Rahmel, Axel and Gummert, Jan F and Khush, Kiran K},
title = {Safety and 1‐Year Outcomes After Transplanting Hearts From SARS‐CoV‐2 Positive Donors: Insights From an International Analysis},
journal = {Immunity, Inflammation and Disease},
year = {2025},
doi = {10.1002/iid3.70252}
}
EUVIMED